San Antonio Breast Cancer Symposium | Conferences

iDFS Not Improved 1-Year of Added Palbociclib to Endocrine Therapy in HR+/HER2- Breast Cancer

December 12, 2020

In the phase 3 PENELOPE-B clinical trial, adding 1 year of palbociclib to endocrine therapy did not demonstrate improvement in invasive disease-free survival in patients with hormone receptor–positive, HER2-negative breast cancer who are at high risk of relapse following neoadjuvant chemotherapy, according to results presented at the 2020 San Antonio Breast Cancer Symposium.

Assay Demonstrates Precise Distant Recurrence Risk and Chemo Benefit Measurement in Early Breast Cancer

December 12, 2020

For patients with node-negative early breast cancer, RSClin, an intergration of the 21-gene expression assay and clinical pathologic features, provided more prognostic information compared with the 21-gene recurrence score or clinical pathologic features alone, as well as a more precise prediction of absolute chemotherapy benefit.

Antiematics and Loperamide Resolve GI AEs Related to Oral Paclitaxel Plus Encequidar in mBC

December 12, 2020

Using 5- HT3 inhibitors and early intervention with loperamide was shown to manage gastrointestinal adverse events oral paclitaxel and encequidar in patients with metastatic breast cancer, according to a study presented during the San Antonio Breast Cancer Symposium.

Sacituzumab Govitecan Shows PFS Benefit for Patients With mTNBC and Brain Metastases

December 11, 2020

Sacituzumab govitecan led to improvements in response rates and progression-free survival (PFS) compared with chemotherapy for patients with metastatic triple-negative breast cancer who had stable brain metastases in a subgroup analysis from the phase 3 ASCENT trial.

Plinabulin/Pegfilgrastim Shows Improved Prevention of Profound Neutropenia in Breast Cancer Versus Chemotherapy

December 11, 2020

In the phase 3 PROTECTIVE-2 trial, patient with breast cancer who received plinabulin and pegfilgrastim experienced a reduction in the incidence of profound neutropenia that was 53% more effective than that of chemotherapy, according to findings presented during the 2020 San Antonio Breast Cancer Symposium.

Better Prediction of Response to Trastuzumab Deruxtecan Analyzed in HER2-Positive Breast Cancer

December 11, 2020

To identify which patients with HER2-positive breast cancer are most likely to respond to fam-trastuzumab deruxtecan-nxki, investigators used a novel HER2 quantitative continuous score to provide a better objective and quantitative assessment of HER2 expression, data presented during the 2020 San Antonio Beast Cancer Symposium show.

GP2/GM-CSF Combination Induces 100% Disease-Free Survival Rate at 5 years in HER2 3+ Breast Cancer

December 11, 2020

The GP2 immunotherapy in combination with granulocyte-macrophage colony-stimulating factor induced a 100% disease-free survival with potent responses as treatment of patients with HER2/neu 3–positive disease who received adjuvant trastuzumab .